$BSX · BOSTON SCIENTIFIC CORP
Boston Scientific entered underwriting agreements on November 19, 2026, pricing $3.0B of USD senior notes (5.375% due 2029 through 5.875% due 2036) and €4.25B of euro notes issued by AMS Europe, fully guaranteed by the Company. Proceeds, with short-term borrowings and cash, fund the Penumbra acquisition cash consideration and related fees. Offerings close December 1, 2026, and are not conditioned on the Penumbra acquisition completing.
- USD offering: $1.0B 5.375% due 2029, $750M 5.500% due 2031, $750M 5.750% due 2033, $500M 5.875% due 2036.
- Euro offering: €4.25B across six tranches, including €500M floating-rate notes due 2028 and €750M 5.125% due 2046.
- Euro notes fully and unconditionally guaranteed by Boston Scientific.
- Special mandatory redemption at 101% of principal if Penumbra acquisition not completed by the applicable end date.
- Neither offering is conditioned on completion of the other offering.
Price data unavailable.
Boston Scientific is raising roughly $7.7B equivalent in debt to finance its Penumbra acquisition, a major medtech consolidation move.
_Not applicable._
If the Penumbra acquisition fails to close by the special mandatory redemption end date, each note series must be redeemed at 101% of principal plus accrued interest.